Bioventus shared its earnings for the third quarter of 2026, showing a 3% rise in sales.

Nov 2, 2026, 5:32 PM ETResultsRead the original at Benzinga

Neutral

Bioventus reported 3% sales growth and higher adjusted EBITDA, but lowered its full-year sales forecast because of weakness in bone graft substitutes. It kept its adjusted profit-per-share forecast, so the report does not point clearly in one direction.

BVS · Bioventus

AI read · Neutral

The AI's read

Pain treatments and international sales showed strength, but bone graft substitutes remained weak. Bioventus is investing in several growth areas, and its review of options after outside acquisition interest is still underway. No outcome was announced, and the lower sales forecast tempers the stronger profit results.

Get alerts for BVS

Follow Bioventus (BVS) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for BVS

Free on the App Store and Google Play, or on the web.